Evidence map›Paper›PMID 42004464›Full record

ArticleCase reports in urology2026

Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.

Roosvelt Tessa Djambong, Bril Laurel Follah Feudjio, Stéphane Rysselinck, Emmanuel Seront, Günter Niegisch, Christina Neppl, Alexander Müller

Abstract read
In one paragraph

Article in Case reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roosvelt Tessa DjambongDepartment of Internal Medicine, Hôpital du Jura, Delémont, Switzerland, h-ju.ch.ORCID https://orcid.org/0009-0003-2839-7265
Bril Laurel Follah FeudjioDepartment of Urology, Uroviva Spital Limmattal, Schlieren, Switzerland.
Stéphane RysselinckDepartment of Urology, CHU HELORA La Louvière-Site Jolimont, La Louvière, Belgium.
Emmanuel SerontDepartment of Medical Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium, saintluc.be.ORCID https://orcid.org/0000-0003-4807-7472
Günter NiegischDepartment of Urology, Medical Faculty and University Hospital, Heinrich-Heine-University, Düsseldorf, Germany, uni-duesseldorf.de.ORCID https://orcid.org/0000-0001-6929-8691
Christina NepplCenter for Integrated Oncology (CIO) Düsseldorf, CIO Aachen-Bonn-Köln-Düsseldorf, Düsseldorf, Germany.
Alexander MüllerDepartment of Urology, Uroviva Spital Limmattal, Schlieren, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, characterized by its high degree of vascularity and metastatic potential. Although common metastatic sites include the lungs, lymph nodes, bones, liver, adrenal glands, and brain, rare localizations, such as those observed in the pancreas, gallbladder, thyroid gland, and nasal cavities, pose significant diagnostic and therapeutic challenges. Case presentation: The following report details four cases of ccRCC with atypical metastatic localizations: A nasal metastasis in one patient, a thyroid metastasis in one patient, a gallbladder metastasis in one patient, and pancreatic localizations in all four patients. These metastases, frequently asymptomatic, contributed to delays in diagnosis. The therapeutic management of these cases was individualized, incorporating surveillance, surgical intervention, radiotherapy, or immunotherapy, depending on the patient's clinical profile and the progression of the lesions. Conclusion: This series illustrates the diversity of metastatic presentations of ccRCC and highlights the importance of prolonged, personalized follow-up after nephrectomy. A multidisciplinary approach remains essential for the timely detection and optimal management of rare metastatic sites.

Indexed as

biliary metastasesclear cell renal cell carcinomanasal metastasespancreatic metastasesthyroid metastases

Identifiers

PMID42004464
PMCPMC13084330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.